A lymphomagenic role for HIV beyond immune suppression?

Blood

Volumn 127, Issue 11, 2016, Pages 1403-1409

  Dolcetti, Riccardo ^a,b   Gloghini, Annunziata ^c   Caruso, Arnaldo ^d   Carbone, Antonino ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; PROTEIN P17; TRANSACTIVATOR PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 2;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BURKITT LYMPHOMA; CANCER CONTROL; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CLASSICAL HODGKIN LYMPHOMA; CLONOGENESIS; DISEASE ASSOCIATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMAGENESIS; LYMPHOPROLIFERATIVE DISEASE; PATHOGENESIS; PLASMABLASTIC LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; TUMOR MICROENVIRONMENT; ANIMAL; CELL CLONE; CLASSIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GERMINAL CENTER; IMMUNOCOMPROMISED PATIENT; LYMPHOCYTE ACTIVATION; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MOUSE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; STRUCTURAL GENE; TRANSGENIC MOUSE; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CLONE CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, GAG; GERMINAL CENTER; HIV; HIV ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOCYTE ACTIVATION; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; TUMOR MICROENVIRONMENT;

EID: 84962558674     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-681411     Document Type: Article

References (56)

1. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-762.
2. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117(5):1089-1096.
3. Vandenhende MA, Roussillon C, Henard S, et al. ANRS EN20 Mortalit é 2010 study group. Cancerrelated causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS One. 2015;10(6):e0129550.
4. Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11(4):223-238.
5. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015;42(2):247-257.
6. Pantanowitz L, Carbone A, Dolcetti R. Microenvironment and HIV-related lymphomagenesis. Semin Cancer Biol. 2015;34:52-57.
7. Martorelli D, Muraro E, Mastorci K, et al. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. Int J Cancer. 2015;137(6):1374-1385.
8. Dolcetti R, Giagulli C, He W, et al. Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci USA. 2015;112(46):14331-14336.
9. Zoufaly A, Stellbrink HJ, Heiden MA, et al; ClinSurv Study Group. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200(1):79-87.
10. Achenbach CJ, Buchanan AL, Cole SR, et al; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014;58(11):1599-1606.
11. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517-534.
12. Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015;34(36):4673-4682.
13. Carbone A, Younes A. Lymphomas and microenvironment: Impact on lymphomagenesis. Foreword. Semin Cancer Biol. 2015;34:1-2.
14. Raphael M, Said J, Borish B, Cesarman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008:340-342.
15. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213-1224.
16. Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol. 2013;23(6):457-467.
17. Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1069-1078.
18. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313-2318.
19. Arvey A, Ojesina AI, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas. Blood. 2015;125(20):e14-e22.
20. Chadburn A, Abdul-Nabi AM, Teruya BS, Lo AA. Lymphoid proliferations associated with human immunodeficiency virus infection. Arch Pathol Lab Med. 2013;137(3):360-370.
21. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. A review of human carcinogens. Part B: biological agents. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Vol. 100, Lyon: 2012.
22. De Paoli P, Carbone A. Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis. Semin Cancer Biol. 2015;34:70-80.
23. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4(1):22-29.
24. Morton LM, Kim CJ, Weiss LM, et al. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. Leuk Lymphoma. 2014;55(3):551-557.
25. Riedel DJ, Rositch AF, Redfield RR, Blattner WA. HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population [published online ahead of print June 19, 2015]. Blood.
26. Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11(4):375-383.
27. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3):744-751.
28. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist. 2008;13(5):577-585.
29. Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216(4):440-450.
30. Leucci E, Onnis A, Cocco M, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNAaltered expression. Int J Cancer. 2010;126(6):1316-1326.
31. Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 2014;93(8):1263-1277.
32. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
33. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88(2):645-656.
34. Carbone A, Cesarman E, Gloghini A, Drexler HG. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS. 2010;24(4):479-490.
35. Fan W, Bubman D, Chadburn A, Harrington WJ Jr, Cesarman E, Knowles DM. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol. 2005;79(2):1244-1251.
36. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:256-257.
37. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-2330.
38. Wang H-Y, Wong-Sefidan I, Reid E. Plasmablastic lymphoma. In: Yarchoan E, ed. Cancers in People with HIV and AIDS. New York: Springer; 2014:223-234.
39. Carbone A, De Paoli P, Gloghini A, Vaccher E. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2015;137(2):251-261.
40. Polizzotto MN, Uldrick TS, Yarchoan R. Multicentric Castleman disease. In: Yarchoan E, ed. Cancers in People with HIV and AIDS. New York: Springer; 2014:245-260.
41. Vendrame E, Hussain SK, Breen EC, et al. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIVassociated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. 2014;23(2):343-349.
42. Martin G, Roy J, Barat C, Ouellet M, Gilbert C, Tremblay MJ. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD41 T cells. J Virol. 2007;81(11):5872-5881.
43. Imbeault M, Ouellet M, Giguère K, et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J Virol. 2011;85(5):2189-2200.
44. Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev. 2010;237(1):226-248.
45. Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell. 2009;36(4):631-641.
46. Curreli S, Krishnan S, Reitz M, et al. B cell lymphoma in HIV transgenic mice. Retrovirology. 2013;10:92.
47. Kundu RK, Sangiorgi F, Wu LY, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 1999;94(1):275-282.
48. Lazzi S, Bellan C, De Falco G, et al. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol. 2002;33(7):723-731.
49. Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med. 1994;179(3):961-971.
50. Blazevic V, Heino M, Lagerstedt A, Ranki A, Krohn KJ. Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(3):208-214.
51. Srivastava DK, Tendler CL, Milani D, English MA, Licht JD, Wilson SH. The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase. AIDS. 2001;15(4):433-440.
52. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDSassociated pathologies. Angiogenesis. 2002;5(3):141-151.
53. Popovic M, Tenner-Racz K, Pelser C, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2005;102(41):14807-14812.
54. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One. 2011;6(3):e17831.
55. Caccuri F, Giagulli C, Reichelt J, et al. Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol. 2014;88(10):5706-5717.
56. Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012;122(10):3439-3447.